Why is the Paradigm (ASX:PAR) share price climbing today?

The Paradigm (ASX: PAR) share price is up 2.8% after the company reported a loss in its first-half FY21 earnings. Here's a closer look.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price gained ground today and is presently trading at $2.55 a share, a 2.82% bounce.

The share price increase comes after Paradigm released its 1HY21 financial results.

Here's the rundown of what we found out. 

Medical staff wear hero capes, indicting strong shar [price performace for healthcare shares

Image source: Getty Images

Paradigm share price rises after company reports loss

Paradigm reported a net profit after taxes (NPAT) loss of $20.7 million for 1HY21. This compares to the $5.1 million loss reported for 1HY20.

The company advised that the increased NPAT loss was a product of the significant progress made with its osteoarthrosis (OA) and mucopolysaccharidosis (MPS) clinical programs.

Specifically, the company incurred the costs and expenses reflected in the NPAT loss in order to launch phase II and phase III trials for the treatment of MPS. Paradigm also allocated additional expenses to convene meetings pertaining to OA with the United States Food and Drug Administration and European Medicines Agency.

As of 31 December 2020, Paradigm posted $95.3 million worth of assets. $112.4 million in total assets was reported for the 1HY20 period.

Cash and cash equivalents totalled $85.2 million for 1HY21 compared to $80 million for 1HY20.

The company received a $3.4 million R&D tax incentive during 1Hy21.

Chief medical officer shares insight

Paradigm chief medical officer Dr Donna Skerrett commented on Paradigm's progress during the period, saying: 

During CY 2020, Paradigm conducted a number of non-clinical and clinical studies to provide updated information regarding drug characteristics, pharmacokinetics, and non-clinical toxicity as requested by the FDA in the company's first meeting with the agency in February 2020.

Paradigm has worked diligently to ensure it has all the necessary supporting non-clinical and clinical data and clinical development plan to support its IND submission in Q1 CY 2021.

Paradigm share price snapshot

Over the past year, the Paradigm share price has dropped about 26%.

The company's market capitalisation is $578.2 million. Paradigm currently has 225.9 million shares outstanding.

Motley Fool contributor Gretchen Kennedy has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ASX Share Market News

Ten smiling business people wave to the camera after receiving some winning company news.
Share Gainers

Here are the top 10 ASX 200 shares today

It was an exceedingly positive Tuesday for investors.

Read more »

A boy is about to rocket from a copper-coloured field of hay into the sky.
ASX Share Market News

Brokers tip these 3 ASX 200 shares to return 28% to 38%

Find out which of these ASX 200 shares has the strongest upside.

Read more »

A woman stands in a field and raises her arms to welcome a golden sunset.
Gold

4 ASX 200 gold shares to buy: Experts

Experts explain their buy ratings following these miners' June quarter reports.

Read more »

Happy teen friends jumping in front of a wall.
Share Gainers

4 ASX shares rated a buy with upside of up to 187%

All these ASX shares are climbing higher today.

Read more »

Three balls at various places on a cycle.
Broker Notes

6 ASX uranium shares to buy ahead of yellow cake rising to US$200 per pound: experts

This broker tips 83% to 295% upside over 12 months for its 6 top ASX uranium share picks.

Read more »

A hipster-looking man with bushy beard and multiple arm tattoos sits on the floor against a sofa reading a tablet with his hand on his chin as though he is deep in thought.
Broker Notes

Buy, hold, sell: Capstone Copper, Lindsay Australia, Woodside shares

Let's take a look at three fresh buy, hold, and sell calls from the experts. 

Read more »

A man in a business suit scratches his head looking at a graph that started high then dips, then starts to go up again like a rollercoaster.
Broker Notes

Down 23% and 58%, should I buy TechnologyOne and Xero shares now?

A leading expert provides his forecasts for TechnologyOne and Xero shares.

Read more »

An analyst wearing a dark blue shirt and glasses sits at his computer with his chin resting on his hands.
Broker Notes

Buy, hold, sell: Ramsay Healthcare, Xero, Electro Optic Systems shares

Let's take a look at three fresh buy, hold, and sell calls from the experts. 

Read more »